These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 7859136

  • 1. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
    Hughes WT.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar 01; 8(3):247-52. PubMed ID: 7859136
    [Abstract] [Full Text] [Related]

  • 2. Atovaquone: a review.
    Haile LG, Flaherty JF.
    Ann Pharmacother; 1993 Dec 01; 27(12):1488-94. PubMed ID: 8305784
    [Abstract] [Full Text] [Related]

  • 3. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
    Spencer CM, Goa KL.
    Drugs; 1995 Jul 01; 50(1):176-96. PubMed ID: 7588086
    [Abstract] [Full Text] [Related]

  • 4. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
    Korraa H, Saadeh C.
    South Med J; 1996 Mar 01; 89(3):272-7. PubMed ID: 8604455
    [Abstract] [Full Text] [Related]

  • 5. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.
    Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott JD, Gathe JC, Haghighat DP, Sampson JH, Spotkov J, Deresinski SC, Meyer RD, Lancaster DJ.
    Ann Intern Med; 1994 Aug 01; 121(3):174-80. PubMed ID: 7880228
    [Abstract] [Full Text] [Related]

  • 6. Optimizing PCP therapy.
    Torres G, Cadman J.
    GMHC Treat Issues; 1997 Oct 01; 11(10):3-5. PubMed ID: 11364821
    [Abstract] [Full Text] [Related]

  • 7. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
    Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C.
    N Engl J Med; 1993 May 27; 328(21):1521-7. PubMed ID: 8479489
    [Abstract] [Full Text] [Related]

  • 8. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T, Seo K, Yoshino Y, Asako K, Kikuchi H, Kono H, Ota Y.
    J Infect Chemother; 2019 May 27; 25(5):351-354. PubMed ID: 30711257
    [Abstract] [Full Text] [Related]

  • 9. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T.
    Bone Marrow Transplant; 1999 Oct 27; 24(8):897-902. PubMed ID: 10516703
    [Abstract] [Full Text] [Related]

  • 10. Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.
    Zarkin GA, Bala MV, Wood LL, Bennett CL, Simpson K, Dohn MN.
    Pharmacoeconomics; 1996 Jun 27; 9(6):525-34. PubMed ID: 10160480
    [Abstract] [Full Text] [Related]

  • 11. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.
    Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA, Scott J, Marina R, Caldwell P.
    J Infect Dis; 1999 Aug 27; 180(2):369-76. PubMed ID: 10395851
    [Abstract] [Full Text] [Related]

  • 12. Atovaquone: a new antipneumocystis agent.
    Artymowicz RJ, James VE.
    Clin Pharm; 1993 Aug 27; 12(8):563-70. PubMed ID: 8222520
    [Abstract] [Full Text] [Related]

  • 13. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia.
    Hughes WT, LaFon SW, Scott JD, Masur H.
    J Infect Dis; 1995 May 27; 171(5):1295-301. PubMed ID: 7751706
    [Abstract] [Full Text] [Related]

  • 14. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA.
    Arch Intern Med; 2002 Apr 22; 162(8):921-8. PubMed ID: 11966344
    [Abstract] [Full Text] [Related]

  • 15. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].
    Groll AH, Ritter J, Müller FM.
    Klin Padiatr; 2001 Sep 22; 213 Suppl 1():A38-49. PubMed ID: 11577363
    [Abstract] [Full Text] [Related]

  • 16. Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration.
    Cotton D.
    AIDS Clin Care; 1995 Jul 22; 7(7):62. PubMed ID: 11362554
    [Abstract] [Full Text] [Related]

  • 17. Treatment of Pneumocystis carinii pneumonia in adults with AIDS.
    Deresinski SC.
    Semin Respir Infect; 1997 Jun 22; 12(2):79-97. PubMed ID: 9195673
    [Abstract] [Full Text] [Related]

  • 18. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
    Moorman AC, Von Bargen JC, Palella FJ, Holmberg SD.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct 01; 19(2):182-8. PubMed ID: 9768629
    [Abstract] [Full Text] [Related]

  • 19. FDA approves new PCP drug. Food and Drug Administration.
    AIDS Alert; 1995 Aug 01; 10(8):108. PubMed ID: 11362680
    [Abstract] [Full Text] [Related]

  • 20. [Therapy and prevention of pneumocystis carinii pneumonia].
    Goebel FD, Bogner JR.
    Internist (Berl); 1995 Dec 01; 36(12):1150-5. PubMed ID: 8567220
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.